VTUS Key Stats
- Ventrus Bio Poised For Run-Up Into Second Round Of Phase III Results Nov 26
- VENTRUS BIOSCIENCES INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 25
- Ventrus Biosciences Completes Enrollment of Second Pivotal Phase 3 Trial of Diltiazem Cream (VEN 307) in Patients With Anal Fissure noodls Nov 25
- VENTRUS BIOSCIENCES INC Financials Nov 20
- VENTRUS BIOSCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhi Sep 13
- Ventrus keeps rising, OvaScience fall persists after big market moves Sep 12
- Shares Of Ventrus Biosciences Are Poised To Return To $12 Sep 12
- Ventrus soars, OvaScience slides as small caps see diverging fortunes Sep 11
- Ventrus climbs on anal fissure drug studies Sep 11
- VENTRUS BIOSCIENCES INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 11
VTUS Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Ventrus Biosciences is up 32.47% over the last year vs S&P 500 Total Return up 30.43%, Merck up 15.18%, and Biostar Pharmaceuticals up 108.6%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Balance Sheet View Statement
Pro Ratings for VTUS
Pro Strategies Featuring VTUS
Did Ventrus Biosciences make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Ventrus Biosciences, Inc. is a development stage specialty pharmaceutical company. The Company is engaged in the late-stage clinical development of gastrointestinal products in areas of unmet need, anal fissures, and fecal incontinence.